• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapy and medications are not effective. A customized treatment could be the answer.

Cue is an intervention platform that transforms passively acquired sensor data from smartphones into personalized micro-interventions that improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to identify their feature predictors and uncover distinct features that deterministically change mood with time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 However, only about half of those suffering from the disorder receive treatment1. To improve outcomes, healthcare professionals must be able identify and treat patients who are most likely to respond to specific treatments.

Personalized depression treatment can help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit the most from specific treatments. They use sensors on mobile phones as well as a voice assistant that incorporates artificial intelligence as well as other digital tools. With two grants totaling over $10 million, they will make use of these technologies to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.

The majority of research to so far has focused on sociodemographic and clinical characteristics. These include demographic factors like age, sex and education, clinical characteristics such as the severity of symptoms and comorbidities and biological indicators such as neuroimaging and genetic variation.

A few studies have utilized longitudinal data to determine mood among individuals. A few studies also consider the fact that mood can be very different between individuals. Therefore, it is crucial to develop methods which allow for the identification and quantification of individual differences in mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can systematically identify various patterns of behavior and emotion that differ between individuals.

The team also devised an algorithm for machine learning to create dynamic predictors for each person's depression mood. The algorithm blends the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, a psychometrically validated symptom severity scale. The correlation was low however (Pearson r = 0,08, P-value adjusted by BH 3.55 10 03) and varied widely between individuals.

Predictors of symptoms

Depression is one of the leading causes of disability1 but is often untreated and not diagnosed. Depression disorders are rarely treated because of the stigma that surrounds them and the lack of effective treatments.

To assist in individualized treatment, it is important to identify predictors of symptoms. Current prediction methods rely heavily on clinical interviews, which are unreliable and only detect a few symptoms associated with depression.

Machine learning can be used to combine continuous digital behavioral phenotypes that are captured by sensors on smartphones and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory the CAT-DI) with other predictors of symptom severity can improve the accuracy of diagnosis and the effectiveness of treatment for depression. Digital phenotypes permit continuous, high-resolution measurements and capture a wide variety of distinctive behaviors and activity patterns that are difficult to record with interviews.

The study enrolled University of California Los Angeles (UCLA) students with moderate to severe depressive symptoms. who were enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were directed to online support or to clinical treatment according to the severity of their depression. Participants with a CAT-DI score of 35 65 were allocated online support via an online peer coach, whereas those who scored 75 patients were referred ketamine for treatment resistant depression treatment centers near me (This Web site) psychotherapy in-person.

Participants were asked a set of questions at the beginning of the study concerning their demographics and psychosocial characteristics. These included sex, age and education, as well as work and financial situation; whether they were partnered, divorced or single; their current suicidal ideas, intent or attempts; and the frequency at which they drank alcohol. Participants also scored their level of depression severity on a scale of 0-100 using the CAT-DI. The CAT DI assessment was conducted every two weeks for those who received online support, and weekly for those who received in-person care.

Predictors of Treatment Reaction

A customized treatment for depression is currently a major research area and many studies aim to identify predictors that allow clinicians to identify the most effective medications for each patient. Pharmacogenetics, for instance, identifies genetic variations that determine the way that our bodies process drugs. This enables doctors to choose the medications that are most likely to work best treatment for severe depression for each patient, while minimizing the time and effort involved in trial-and-error procedures and eliminating any side effects that could otherwise slow advancement.

Another option is to build prediction models that combine information from clinical studies and neural imaging data. These models can be used to determine the variables that are most predictive of a specific outcome, like whether a medication can help with symptoms or mood. These models can be used to determine the response of a patient to an existing treatment, allowing doctors to maximize the effectiveness of the current therapy.

A new era of research utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables and increase predictive accuracy. These models have proven to be useful in the prediction of treatment refractory depression outcomes like the response to antidepressants. These methods are becoming more popular in psychiatry, and are likely to be the norm in future treatment.

Research into depression's underlying mechanisms continues, in addition to ML-based predictive models. Recent research suggests that depression is related to the dysfunctions of specific neural networks. This theory suggests that an individualized treatment for depression will be based on targeted treatments that restore normal function to these circuits.

Internet-delivered interventions can be an effective method to accomplish this. They can provide a more tailored and individualized experience for patients. For example, one study found that a program on the internet was more effective than standard care in improving symptoms and providing a better quality of life for people suffering from MDD. A randomized controlled study of a personalized treatment for depression revealed that a significant number of participants experienced sustained improvement and fewer side consequences.

Predictors of adverse effects

A major obstacle in individualized depression treatment is predicting which antidepressant medications will cause the least amount of side effects or none at all. Many patients have a trial-and error approach, using a variety of medications being prescribed before settling on one that is safe and effective. Pharmacogenetics provides a novel and exciting method to choose antidepressant drugs that are more effective and precise.

There are a variety of variables that can be used to determine the antidepressant that should be prescribed, such as gene variations, phenotypes of the patient like gender or ethnicity, and the presence of comorbidities. To identify the most reliable and reliable predictors for a particular treatment, controlled trials that are randomized with larger sample sizes will be required. This is because it could be more difficult to determine interactions or moderators in trials that only include one episode per participant instead of multiple episodes spread over time.

Furthermore, predicting a patient's response will likely require information on the severity of symptoms, comorbidities and the patient's subjective perception of the effectiveness and tolerability. Currently, only some easily assessable sociodemographic and clinical variables are believed to be reliably associated with the response to MDD factors, including gender, age, race/ethnicity and SES, BMI, the presence of alexithymia, and the severity of depression symptoms.

Many challenges remain in the application of pharmacogenetics in the treatment of depression. First it is necessary to have a clear understanding of the genetic mechanisms is needed, as is a clear definition of what treatment for depression constitutes a reliable predictor for treatment response. Ethics such as privacy and the responsible use genetic information should also be considered. In the long term pharmacogenetics can be a way to lessen the stigma associated with mental health treatment and improve the natural treatment for anxiety and depression outcomes for patients with depression. As with all psychiatric approaches, it is important to take your time and carefully implement the plan. For now, it is best to offer patients an array of depression medications that are effective and encourage them to speak openly with their physicians.